Medicine details
| Image |  |
| Name | Pegferon 180 |
| Dosage | Injection |
| Generic Name | Peginterferon Alfa-2a |
| Classes |
Antiinfective Agent Antiviral Agent Antiviral Combination |
| Diseases |
Hepatitis B Hepatitis C Infectious Disease |
| Company | Healthcare Pharmaceuticals Ltd. |
Drug Package Details
| Strength | 180 mcg/vial |
| Storage Condition | |
| Origin Country | Bangladesh |
| Commercial Pack | 1 |
| Price per pack | ৳ 15,000.00 |
| Cost per pack | ৳ 13,200.00 |
| Package unit | 180 mcg pre filled syringe |
| Price per unit | ৳ 15,000.00 |
| Cost per unit | ৳ 13,200.00 |
| Discount | 0 |
| Coupon | |
| Remarks |
Peginterferon Alfa-2a
Interferon alpha 2a is recombinant interferon, a cytokine. Peginterferon Alfa-2a refers to polyethylene glycated interferon. Peginterferon Alfa-2a's biological activity is derived from its recombinant human interferon-2a moiety. Peginterferon-2a binds to the human type 1 interferon receptor, causing it to dimerize. Multiple intracellular signal transduction pathways are activated by receptor dimerization, which is initiated by the JAK/STAT pathway. Peginterferon-2a is expected to have pleiotropic biological effects in the body due to the diversity of cell types that respond to interferon-2a and the multiplicity of potential intracellular responses to interferon receptor activation.
- Interferon alpha 2a is administered by subcutaneous injection.
- In adult patients with chronic hepatitis C or chronic hepatitis B, Interferon alpha 2a is dosed as 180 mcg per week and the duration of treatment depends on indication, genotype, and whether it is administered with Ribavirin.
- In pediatric patients with CHC, Interferon alpha 2a is dosed as 180 mcg/1.73 m2 x BSA per week, in combination with Ribavirin, and the duration of treatment depends on genotype.
- Dose reduction is recommended in patients experiencing certain laboratory abnormalities, adverse reactions or renal impairment.
It has the potential to cause or worsen fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. With persistently severe or worsening signs or symptoms of the aforementioned disorders, discontinue therapy.
Ribavirin use:
- Ribavirin may cause birth defects and fetal death; female patients and female partners of male patients should avoid pregnancy.
- Birth defects and fetal death: patients must have a negative pregnancy test prior to therapy, use 2 or more forms of contraception, and have monthly pregnancy tests
- Hemolytic anemia
- History of significant or unstable cardiac disease
Patients exhibiting the following events should be closely monitored and may require dose reduction or discontinuation of therapy:
- Neuropsychiatric events
- Autoimmune and endocrine disorders (including thyroid disorders; hyperglycemia)
- Ophthalmologic disorders
- Cerebrovascular disorders
- Hepatic decompensation in cirrhotic patients. Exacerbation of hepatitis during hepatitis B treatment.
- Pulmonary disorders
- Infections (bacterial, viral, fungal)
- Bone marrow suppression
- Colitis and pancreatitis
- Hypersensitivity and serious skin reactions including Stevens-Johnson syndrome
- Growth impairment with combination therapy in pediatric patients
- Peripheral neuropathy when used in combination with telbivudine
Contraindication
None known.
None known.
Bangla
English